Inhibitor

Bibliography

Biblio print

Tree Display

AceDB Schema

XML Display

Feedback

Inhibitor Report for: Evogliptin

Derivative of DA-1266. DDP4 IC50 0.666 nM


General
Type Drug, Gliptin, Trifluoro
Chemical_Nomenclature (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(2-methylpropan-2-yl)oxymethyl]piperazin-2-one
Canonical SMILES CC(C)(C)OCC1C(=O)NCCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N
InChI InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1
InChIKey LCDDAGSJHKEABN-MLGOLLRUSA-N
Other name(s) 8VU ; DA-1229 ; DA1229 ; UNII-09118300L7 ; CHEMBL1779710
________________________________________________________________________________________________
MW|401.43
Formula|C19H26F3N3O3
CAS_number|1222102-29-5
PubChem|25022354
UniChem|LCDDAGSJHKEABN-MLGOLLRUSA-N
IUPHAR|
Wikipedia|Evogliptin

Target
Families | Evogliptin ligand of proteins in family: DPP4N_Peptidase_S9
Stucture | 1 structure: 5Y7K: Crystal structure of human DPP4 in complex with inhibitor Evogliptin
Protein | human-DPP4

References:
Search PubMed for references concerning: Evogliptin

13 more
    Title: Pharmacokinetics and safety of evogliptin in hepatically impaired patients
    Hong T, Jin BH, Kim CO, Yoo BW, Kim D, Lee JI, Kim BK, Ahn SH, Kim DY and Park MS <1 more author(s)>
    Ref: British Journal of Clinical Pharmacology, 87:2757, 2021 : PubMed

            

    Title: Unique binding mode of Evogliptin with human dipeptidyl peptidase IV
    Lee HK, Kim MK, Kim HD, Kim HJ, Kim JW, Lee JO, Kim CW, Kim EE
    Ref: Biochemical & Biophysical Research Communications, 494:452, 2017 : PubMed

            

    Title: Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes
    Tan X, Hu J
    Ref: Expert Opin Pharmacother, 17:1285, 2016 : PubMed